<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00165867</url>
  </required_header>
  <id_info>
    <org_study_id>E7070-E044-214</org_study_id>
    <nct_id>NCT00165867</nct_id>
  </id_info>
  <brief_title>An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and Oxaliplatin</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      The overall purpose of this study is to determine the efficacy, safety and tolerability of&#xD;
      indisulam in combination with irinotecan as a treatment for patients with metastatic&#xD;
      colorectalcancer previously treated with 5-fluorouracil/leucovorin and oxaliplatin (FOLFOX).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The objective response rate as defined by RECIST criteria.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability of the combination</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E7070</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Ambulant male or female patients with metastatic colorectal cancer who have been&#xD;
             previously treated with 5-fluorouracil/leucovorin and oxaliplatin. Patients must&#xD;
             fulfill the following criteria to be included in the study:&#xD;
&#xD;
          -  At least 4 doses of previous treatment with oxaliplatin&#xD;
&#xD;
          -  All previous treatment (including surgery and radiotherapy) must have been completed&#xD;
             at least four weeks prior to study entry and any acute toxicities must have resolved&#xD;
&#xD;
          -  At least one uni-dimensionally measurable lesion according to RECIST criteria (the&#xD;
             following do not qualify as measurable lesions: bone, leptomeningeal disease, ascites,&#xD;
             pleural/pericardial effusion, lymphangitis cutis/pulmonis, abdominal masses that are&#xD;
             not confirmed and followed by imaging techniques, and cystic lesions)&#xD;
&#xD;
          -  Aged greater than or equal to 18 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed colorectal cancer&#xD;
&#xD;
          -  Karnofsky performance status greater than or equal to 70%&#xD;
&#xD;
          -  Written informed consent to participate in the study&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Patients with the following characteristics will not be included in the study:&#xD;
&#xD;
          -  More than three previous lines of chemotherapy (including neo-adjuvant and adjuvant)&#xD;
&#xD;
          -  Prior treatment with cytotoxics other than 5- fluorouracil/leucovorin (capecitabine&#xD;
             and UFT are permitted) and oxaliplatin. Prior epidermal growth factor receptor&#xD;
             targeted and anti-angiogenic therapy is permitted.&#xD;
&#xD;
          -  Untreated brain metastases (patients who have been treated for CNS metastases must be&#xD;
             asymptomatic and radiologically stable for 4 weeks prior to entry). Patients must not&#xD;
             have clinical symptoms from brain metastases and must not be taking corticosteroids&#xD;
             for the treatment of brain metastases. Patients must not have leptomeningeal&#xD;
             metastases&#xD;
&#xD;
          -  Any of the following laboratory parameters:&#xD;
&#xD;
               1. hemoglobin &lt;10 g/dl;&#xD;
&#xD;
               2. neutrophils &lt;1.5 x 109/L;&#xD;
&#xD;
               3. platelets &lt;100 x 109/L;&#xD;
&#xD;
               4. serum bilirubin &gt;25 mmol/l (1.5 mg/dl);&#xD;
&#xD;
               5. other liver parameters &gt;2.5 x upper normal limit (ULN) (&gt; 5 x upper normal limit&#xD;
                  in the presence of hepatic metastases);&#xD;
&#xD;
               6. serum creatinine &gt;1.5 x ULN;&#xD;
&#xD;
               7. serum calcium (corrected for albumin) &gt;=11.5 mg/dl. 5. History of Gilbert's&#xD;
                  Disease or conjugated hyperbilirubinemia 6. Concurrent or previous malignancy of&#xD;
                  a different tumor type within five years of starting the study except for&#xD;
                  adequately treated non- melanoma skin cancer or cervical intraepithelial&#xD;
                  neoplasia&#xD;
&#xD;
          -  Uncontrolled infections&#xD;
&#xD;
          -  Clinically significant cardiac impairment or unstable ischemic heart disease including&#xD;
             a myocardial infarction within six months of study start&#xD;
&#xD;
          -  Chronic inflammatory bowel disease and/or bowel obstruction&#xD;
&#xD;
          -  History of hypersensitivity to sulfonamides&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to one of the excipients of irinotecan&#xD;
&#xD;
          -  Treatment within two weeks before the start of the stud y with any of the following:&#xD;
             coumarin anti-coagulants, terfenadine, cisapride, cyclosporin, tacrolimus,&#xD;
             theophylline, diazepam, sulphonylurea hypoglycaemics, phenytoin, or carbamazepine&#xD;
&#xD;
          -  Any treatment with investigational drugs within 30 days before the start of the study&#xD;
&#xD;
          -  Pregnancy or lactation (all women of childbearing potential must have a negative&#xD;
             pregnancy test before inclusion in the study; post-menopausal women must be&#xD;
             amenorrheic for at least 12 months). Female patients must use adequate contraceptive&#xD;
             protection&#xD;
&#xD;
          -  Fertile males not willing to use contraception or whose female partners are not using&#xD;
             adequate contraceptive protection&#xD;
&#xD;
          -  History of alcoholism, drug addiction, or any psychiatric or psychological condition&#xD;
             which, in the opinion of the investigator, would impair study compliance.&#xD;
&#xD;
          -  Legal incapacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jantien Wanders</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HÃ´pitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>F- 68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>F-34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>F-06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson Oncology Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cookridge Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS16 6QB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>October 6, 2006</last_update_submitted>
  <last_update_submitted_qc>October 6, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

